CL2025002112A1 - Anticuerpo anti-npr1; método de producción; y su uso. - Google Patents

Anticuerpo anti-npr1; método de producción; y su uso.

Info

Publication number
CL2025002112A1
CL2025002112A1 CL2025002112A CL2025002112A CL2025002112A1 CL 2025002112 A1 CL2025002112 A1 CL 2025002112A1 CL 2025002112 A CL2025002112 A CL 2025002112A CL 2025002112 A CL2025002112 A CL 2025002112A CL 2025002112 A1 CL2025002112 A1 CL 2025002112A1
Authority
CL
Chile
Prior art keywords
npr1
antibodies
disclosure
production
bind
Prior art date
Application number
CL2025002112A
Other languages
English (en)
Inventor
Dunn Michael
Morton Lori
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2025002112A1 publication Critical patent/CL2025002112A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona anticuerpos monoclonales que se unen a la proteína receptor de péptido natriurético 1 (NPR1), y métodos de uso de los mismos. En diversas modalidades de la divulgación, los anticuerpos son anticuerpos antagonistas totalmente humanos que se unen a NPR1. En algunas modalidades, los anticuerpos de la divulgación son útiles para bloquear la señalización y/o actividad de NPR1, proporcionando así un medio para tratar o prevenir una enfermedad, trastorno o afección asociada con NPR1, incluyendo hipotensión, en humanos.
CL2025002112A 2021-12-06 2025-07-17 Anticuerpo anti-npr1; método de producción; y su uso. CL2025002112A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163286476P 2021-12-06 2021-12-06
US202263310078P 2022-02-14 2022-02-14

Publications (1)

Publication Number Publication Date
CL2025002112A1 true CL2025002112A1 (es) 2025-10-24

Family

ID=85017755

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2024001632A CL2024001632A1 (es) 2021-12-06 2024-05-31 Anticuerpos antagonistas anti-npr1 y métodos de uso de los mismos.
CL2025002112A CL2025002112A1 (es) 2021-12-06 2025-07-17 Anticuerpo anti-npr1; método de producción; y su uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2024001632A CL2024001632A1 (es) 2021-12-06 2024-05-31 Anticuerpos antagonistas anti-npr1 y métodos de uso de los mismos.

Country Status (11)

Country Link
US (1) US12606618B2 (es)
EP (1) EP4444416A1 (es)
JP (1) JP2024542823A (es)
KR (1) KR20240112973A (es)
AU (1) AU2022408149A1 (es)
CA (1) CA3239802A1 (es)
CL (2) CL2024001632A1 (es)
CO (1) CO2024008879A2 (es)
IL (1) IL313265A (es)
MX (1) MX2024006812A (es)
WO (1) WO2023107957A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7879544B2 (en) 2002-07-29 2011-02-01 Hmgene Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20100310561A1 (en) 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
EP2370098A4 (en) 2008-12-03 2013-07-17 Morphosys Ag Antibodies for guanylyl cyclase receptors
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG177640A1 (en) 2009-07-13 2012-02-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9451770B2 (en) 2012-06-08 2016-09-27 Charles Despres Method of activating immune response in plants
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US9987330B2 (en) * 2013-12-05 2018-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing pruritis by blocking natriuretic polypeptide B
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20190135804A1 (en) * 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
MX2020008184A (es) * 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
DK3941946T3 (da) * 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
PH12021553101A1 (en) * 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
EP4259661A1 (en) * 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
EP4277926A1 (en) * 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
US20240327539A1 (en) 2021-10-11 2024-10-03 Regeneron Pharmaceuticals, Inc. Methods of effecting a hemodynamic change by administering an anti-npr1 antibody

Also Published As

Publication number Publication date
MX2024006812A (es) 2024-08-19
WO2023107957A1 (en) 2023-06-15
AU2022408149A1 (en) 2024-05-23
CO2024008879A2 (es) 2024-08-08
JP2024542823A (ja) 2024-11-15
CL2024001632A1 (es) 2025-03-28
US12606618B2 (en) 2026-04-21
CA3239802A1 (en) 2023-06-15
US20230250170A1 (en) 2023-08-10
IL313265A (en) 2024-08-01
EP4444416A1 (en) 2024-10-16
KR20240112973A (ko) 2024-07-19

Similar Documents

Publication Publication Date Title
CL2024000378A1 (es) Anticuerpos anti-npr1 y usos de los mismos.
CO2018014413A2 (es) Anticuerpos anti-c5 y usos de los mismos
ECSP21069105A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CL2024001632A1 (es) Anticuerpos antagonistas anti-npr1 y métodos de uso de los mismos.
NI202000051A (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
CO2023016777A2 (es) Anticuerpos anti-tmprss6 y sus usos
CL2021001704A1 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
CO2023009498A2 (es) Proteínas de inmunoglobulina que se unen a agonistas de npr1
ECSP22056627A (es) Anticuerpos contra la integrina alfa 11 beta 1
EA202191060A1 (ru) Анти-npr1 антитела и их применение
EA201990022A1 (ru) Антитела против c5 и их применение
CO2023000343A2 (es) Anticuerpos terapéuticos anti-emap ii humanizados
MX2026000675A (es) Anticuerpos anti-factor xii/xiia y sus usos
TH1801001908A (th) แอนทิบอดีของตัวรับทรานสเฟอร์รินของมนุษย์/แอนทิ-a-บีทาของมนุษย์ที่จำเป็นสองตำแหน่งและวิธีการของการใช้งาน